PO.CT01.04 · 临床试验

Zidesamtinib治疗既往接受过repotrectinib或taletrectinib治疗的ROS1+NSCLC患者

Zidesamtinib in patients with ROS1 + NSCLC previously treated with repotrectinib or taletrectinib

编号 CT248 展板 13 时间 4/21 02:00–05:00 区域 Section 50 主讲 Geoffrey Liu, MD

分会场 Phase II Clinical Trials

查看 PDF 下载 PDF 🔒 查看 / 下载完整 PDF 需登录并开通下载套餐 · 查看套餐 / 开通 AACR 官方页面

作者与单位 Authors & Affiliations

Geoffrey Liu¹, Alexander E. Drilon², Benjamin Besse³, Gianluca Spitaleri⁴, Jessica J. Lin⁵, Byoung Chul Cho⁶, Tatsuya Yoshida⁷, Daniel Haggstrom⁸, Steven Kao⁹, Aurelie Swalduz¹⁰, Misako Nagasaka¹¹, Benjamin J. Solomon¹², Lorenza Landi¹³, Chiara Bennati¹⁴, Elvire Pons-Tostivint¹⁵, Christophe Dooms¹⁶, A. J. van der Wekken¹⁷, Saiama Waqar¹⁸, Shirish Gadgeel¹⁹, Chia-Chi Lin²⁰, Tetsuro Kondo²¹, Hidetoshi Hayashi²², Daniel Tan²³, Giulia Pasello²⁴, Matteo Duca²⁵, Luis G. Paz-Ares²⁶, Antonio Calles²⁷, Enriqueta Felip²⁸, Julien Mazieres²⁹, Adrianus Johannes de Langen³⁰, Alice T. Shaw³¹, Jonathan W. Riess³², Marina Garassino³³, Elaine Shum³⁴, Christina S. Baik³⁵, Jessica R. Bauman³⁶, D. Ross Camidge³⁷, Chien-Chung Lin³⁸, Gee-Chen Chang³⁹, Dong-Wan Kim⁴⁰, Myung-Ju Ahn⁴¹, Ji-Youn Han⁴², Kiichiro Ninomiya⁴³, Ryo Ariyasu⁴⁴, Ross Andrew Soo⁴⁵, Sanjay Popat⁴⁶, Jürgen Wolf⁴⁷, Maria Rosario García Campelo⁴⁸, Vivek A. Upadhyay⁴⁹, Stephen V. Liu⁵⁰

¹Princess Margaret Hospital, Toronto, ON, Canada,²Memorial Sloan Kettering Cancer Center and Weill Cornell Medical Center, New York, NY,³Paris Saclay University, Gustave Roussy, Villejuif, France,⁴Division of Thoracic Oncology Istituto Europeo di Oncologia, Milan, Italy,⁵Mass General Brigham Cancer Institute, Boston, MA,⁶Yonsei Cancer Center, Seoul, Korea, Republic of,⁷National Cancer Center Hospital, Tokyo, Japan,⁸Levine Cancer, Atrium Health, Charlotte, NC,⁹Chris O'Brien Lifehouse, Camperdown, Australia,¹⁰Centre Léon Bérard, Lyon, France,¹¹University of California Irvine Medical Center, Orange, CA,¹²Peter MacCallum Cancer Centre, Melbourne, Australia,¹³Istituto Nazionale Tumori Regina Elena, IRCCS, Rome, Italy,¹⁴Ospedale Santa Maria Delle Croci, Ravenna, Italy,¹⁵Department of Medical Oncology, University Hospital of Nantes, Nantes, France,¹⁶Department of Respiratory Diseases, University Hospitals Leuven, Leuven, Belgium,¹⁷Department of Pulmonology and Tuberculosis, University of Groningen, University Medical Centre Groningen, Groningen, Netherlands,¹⁸Washington University School of Medicine, St. Louis, MO,¹⁹Henry Ford Cancer Center, Detroit, MI,²⁰National Taiwan University Hospital, Taipei, Taiwan,²¹Kanagawa Cancer Center, Yokohama, Japan,²²Kindai University Hospital, Osaka, Japan,²³National Cancer Centre Singapore, Singapore, Singapore,²⁴Oncologia 2 Istituto Oncologico Veneto IRCCS and Department of Surgery Oncology and Gastroenterology, Padova, Italy,²⁵Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy,²⁶Hospital Universitario 12 de Octubre, Madrid, Spain,²⁷Medical Oncology Department. Hospital General Universitario Gregorio Marañón, Madrid, Spain,²⁸Vall d’Hebron University Hospital and Vall d’Hebron Institute of Oncology, Barcelona, Spain,²⁹Institut Claudius Rigaud, Toulouse, France,³⁰Department of Thoracic Oncology, Antoni van Leeuwenhoek Hospital - Netherlands Cancer Institute, Amsterdam, Netherlands,³¹Dana-Farber Cancer Institute, Boston, MA,³²University of California Davis, Davis Comprehensive Cancer Center, Sacramento, CA,³³University of Chicago, Chicago, IL,³⁴New York University Perlmutter Cancer Center, New York, NY,³⁵Fred Hutchinson Cancer Center, Seattle, WA,³⁶Fox Chase Cancer Center, Philadelphia, PA,³⁷University of Colorado Cancer Center, Aurora, CO,³⁸National Cheng Kung University Hospital and Tainan Hospital, Ministry of Health & Welfare, Tainan, Taiwan,³⁹Chung Shan Medical University Hospital, Taichung, Taiwan,⁴⁰Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea, Republic of,⁴¹Section of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea, Republic of,⁴²National Cancer Center, Tokyo, Japan,⁴³Okayama University Hospital, Okayama, Japan,⁴⁴Japanese Foundation for Cancer Research, Tokyo, Japan,⁴⁵National University Hospital, Singapore, Singapore,⁴⁶Lung Unit, Royal Marsden Hospital, London, United Kingdom,⁴⁷Cologne University Hospital, Köln, Germany,⁴⁸University Hospital A Coruña, CHUAC, A Coruña, Spain,⁴⁹Nuvalent, Inc., Cambridge, MA,⁵⁰Georgetown Lombardi Comprehensive Cancer Center, Washington, DC

摘要 Abstract

中文摘要

引言：临床前数据表明，在研ROS1 TKI zidesamtinib对ROS1（包括ROS1 G2032R耐药突变）具有更强的效力、脑穿透性，以及优于FDA批准的双重TRK/ROS1 TKI repotrectinib和taletrectinib的TRK选择性。在临床环境中最大化ROS1活性（包括CNS内的活性）对于驱动具有临床意义的治疗缓解至关重要。ARROS-1正在评估zidesamtinib治疗晚期/转移性ROS1+NSCLC及其他实体瘤患者（pts）。此处我们报告既往接受过repotrectinib或taletrectinib治疗的NSCLC患者的数据。方法：全球性、单臂、1/2期ARROS-1试验（NCT05118789）的关键研究终点包括客观缓解率（ORR，由BICR依据RECIST v1.1评估）、缓解持续时间（DOR）、颅内ORR（IC-ORR）和安全性。此项疗效分析纳入了既往接受过repotrectinib或taletrectinib治疗、经BICR确认有可测量病灶的ROS1+NSCLC患者，接受zidesamtinib 100 mg每日一次治疗。数据截止日期：2025年9月22日。结果：基线时，可评估疗效患者（结果见表）中，既往接受repotrectinib（n=46）或taletrectinib（n=19）治疗者中位既往接受2种ROS1 TKI（两组范围均为1-4种）和3种既往抗癌治疗（范围分别为1-7和1-6）；63%和53%既往接受过化疗。经本地或中心检测报告ROS1耐药突变分别占35%和42%；活动性CNS疾病分别占46%和53%。疗效参数（RECIST v1.1，BICR）既往repotrectinib±化疗既往taletrectinib±化疗 ORR %（n/n）[95% CI] 41%（19/46）a [27, 57] 47%（9/19）[24, 71] CR n（%）3（7%）a 1（5%）mDOR, m b [95% CI] 15.7 [5.6, NE] NR [5.2, NE] ROS1 G2032R耐药突变 ORR %（n/n）[95% CI] 67%（8/12）[35, 90] 50%（2/4）c [7, 93] CR n（%）1（8%）0 mDOR, m b [95% CI] 15.7 [3.5, NE] NR [NE, NE] 颅内活性 d IC-ORR %（n/n）[95% CI] 44%（8/18）[22, 69] 71%（5/7）[29, 96] IC-CR n（%）2（11%）3（43%）mIC-DOR, m b [95% CI] NR [5.2, NE] NR [5.2, NE] BICR，盲态独立中心评审；CI，置信区间；CR，完全缓解；IC，颅内；m，月；mDOR，中位DOR；NE，不可估计；NR，未达到；ORR，客观缓解率；RECIST v1.1，实体瘤疗效评价标准1.1版。a 1例缓解待确认。b Kaplan-Meier估计值。c 在伴ROS1 D2033N（n=1）和L2086F（n=1）的患者中也观察到缓解。d 包括有可测量（≥5mm）CNS病灶的患者。这些患者组的安全性特征与既往在整体关键性TKI经治研究人群中报告的一致，包括避免了TRK或神经系统不良事件（Drilon AE等，J Thorac Oncol. 2025;20(10)(Suppl 3):S3）。结论：此处呈现的zidesamtinib具有临床意义的活性，包括在伴CNS疾病和ROS1 G2032R耐药突变的患者中，表明许多ROS1+NSCLC在repotrectinib和taletrectinib治疗后仍保持ROS1依赖性。

查看英文原文 English abstract

Introduction: Preclinical data indicates that the investigational ROS1 TKI zidesamtinib offers improved potency against ROS1, including ROS1 G2032R resistance mutation, brain penetrance and TRK selectivity over FDA-approved dual TRK/ROS1 TKIs repotrectinib and taletrectinib. Maximizing ROS1 activity in the clinical setting, including activity in the CNS, is essential to drive clinically meaningful responses to treatment. ARROS-1 is evaluating zidesamtinib in patients (pts) with advanced/metastatic ROS1 + NSCLC and other solid tumors. Here we report data in pts with NSCLC previously treated with repotrectinib or taletrectinib. Methods: Key study endpoints in the global, single arm, phase 1/2 ARROS-1 trial (NCT05118789) include objective response rate (ORR, RECIST v1.1 by BICR), duration of response (DOR), intracranial ORR (IC-ORR), and safety. This efficacy analysis included repotrectinib or taletrectinib previously-treated pts with ROS1 + NSCLC and measurable disease by BICR, treated with zidesamtinib 100 mg QD. Data cut-off: 22 Sep 2025. Results: At baseline, efficacy evaluable pts (results in Table) with prior repotrectinib (n=46) or taletrectinib (n=19) received a median of 2 prior ROS1 TKIs (range 1-4 for either) and 3 prior anticancer therapies (range 1-7 and 1-6, respectively); 63% and 53% received prior chemo. ROS1 resistance mutations by local or central testing were reported in 35% and 42%; active CNS disease in 46% and 53%. Efficacy Parameter (RECIST v1.1, BICR) Prior repotrectinib ± chemo Prior taletrectinib ± chemo ORR % (n/n) [95% CI] 41% (19/46) a [27, 57] 47% (9/19) [24, 71] CR n (%) 3 (7%) a 1 (5%) mDOR, m b [95% CI] 15.7 [5.6, NE] NR [5.2, NE] ROS1 G2032R resistance mutation ORR % (n/n) [95% CI] 67% (8/12) [35, 90] 50% (2/4) c [7, 93] CR n (%) 1 (8%) 0 mDOR, m b [95% CI] 15.7 [3.5, NE] NR [NE, NE] Intracranial Activity d IC-ORR % (n/n) [95% CI] 44% (8/18) [22, 69] 71% (5/7) [29, 96] IC-CR n (%) 2 (11%) 3 (43%) mIC-DOR, m b [95% CI] NR [5.2, NE] NR [5.2, NE] BICR, blinded independent central review; CI, confidence interval; CR, complete response; IC, intracranial; m, months; mDOR, median DOR; NE, not estimable; NR, not reached; ORR, objective response rate; RECIST v1.1, Response Evaluation Criteria in Solid Tumors version 1.1. a 1 response pending confirmation. b Kaplan-Meier estimates. c Responses also observed in pts with ROS1 D2033N (n=1) and L2086F (n=1). d Includes pts with measurable (≥5mm) CNS lesions. The safety profiles in these pt groups were consistent with what was previously reported in the overall pivotal TKI pretreated study population, including the avoidance of TRK or neurological adverse events (Drilon AE, et al. J Thorac Oncol. 2025;20(10)(Suppl 3):S3). Conclusions: The meaningful clinical activity presented here for zidesamtinib, including in pts with CNS disease and ROS1 G2032R resistance mutation, indicates that many ROS1 + NSCLCs remain ROS1-dependent beyond repotrectinib and taletrectinib.

利益披露 Disclosure

G. Liu, Pfizer Other, Advisory role, Speakers' Bureau, Honoraria. Novartis Other, Advisory role, Honoraria. Astrazeneca ), Advisory role, Speakers' bureau, honoraria. MedImmune ), Advisory role. Takeda ), Other, Advisory role, Speakers' bureau, honoraria. Roche Canada Other, Advisory role, honoraria. Merck Other, Honoraria. Abbvie Other, Honoraria. Bayer Other, Honoraria. Bristol-Meyers Squibb Other, Honoraria. Jazz Pharmaceuticals Other, Honoraria. Amgen Other, Honoraria. Nuvation Bio Other, Honoraria. EMB Serono Other, Honoraria. Roche ). Boehringer Ingelheim ). A. E. Drilon, mBRACE; Treeline Stock. MonteRosa; Innocare; Boundless Bio; Treeline; Nuvalent; 14ner/Elevation Oncology; Entos; Prelude; Bayer; Applied Pharmaceutical Science; Bristol Myers Squibb; Enlaza; Pfizer; Roche/Genentech Other, Consulting or advisory role. Novartis; Two River; Lilly/Loxo; Abbvie; Amgen; Helsinn; AnHeart Therapeutics Consulting or advisory role. Foundation Medicine; Teva; Taiho; GlaxSmithKlein; PharmaMar ). Wolters Kluwer; UpToDate; Selpercatinib-Osimertinib (US 18/041,617, pending) Patent, Copyright, Other Intellectual Property. Boehringer Ingelheim; Merck Puma Travel. B. Besse, Abbvie; BioNTech SE; Beijing Avistone Biotechnology; Bristol-Myer Sqibb; Cure Vac AG; PharmaMar; Regeneron; Sanofi Aventis; Eli Lilly; Ellipses Pharma Ltd; F. Hoffman-La Roche Ltd Other, Advisory role. Foghorn Therapeutics; Genmab; Immunocore; Owkin Other, Advisory role. AstraZeneca; Amgen; Beigene; CureVac AG; GENMAB A/S; Janssen; MSD; Ose Immunotherapeutics; PharmaMar; Sanofi; Takeda Other, Steering Committee. Abbvie; AstraZeneca; Bristol-Myer Sqibb; Daiichi Sankyo; Lilly; MSD; Ose Immunotherapeutics; Sanofi Aventis; Servier Other, Speaker. G. Spitaleri, Takeda Other, Advisory role. J. J. Lin, Genentech; Nuvalent; Turning Point Therapeutics; Bayer; Mirati Therapeutics; Novartis; Elevation Oncology; Regeneron; Merus; Yuhan; Daiichi Sankyo/AstraZeneca; Bristol-Myers Squibb; AstraZeneca Other, Consulting, advisory. Ellipses Pharma; CLaiM Therapeutics; Anheart Therapeutics; Pfizer; Takeda; Hyku Biosciences; Lilly; Roche/Genentech; Nuvation Bio; Janssen; Gilead Sciences; Triana; Nuvectis Pharma Other, Consulting, advisory. Pfizer; Merus; Takeda; Briston-Myers Squibb Travel. Turning Point Therapeutics; Novartis; Relay Therapeutics; Elevation Oncology; Bayer; Roche; Linnaeus Therapeutics; Nuvalent; Pfizer; Bristol-Myers Squibb; Sutro Biopharma; Summit Therapeutics ). Lilly; Bicycle Therapeutics; Genentech ). OncLive; PeerView; Curio Science; HMP Education; Medscape; Answers in CME; TotalCME; Clinical Care Options Other, Honoraria. B. Cho, Yonsei University Health System Employment. AstraZeneca; Boehringer Ingelheim; Roche; Yuhan; Pfizer; Janssen; Takeda; MSD; Lilly; Novartis; CJ Bioscience; BeiGene; Bristol-Myers Squibb; Ono Pharmaceutical; Cyrus Therapeutics; Gilead Sciences Other, Advisory role. Amgen; Daiichi Sankyo; Regenerol; AnHeart Therapeutics; Seagen; Harpoon Therapeutics; GlaxoSmithKline; ArriVent Biopharma; Bridgebio; Kanaph Therapeutics; Cyrus Therapeutics; Guardant Health Other, Advisory role. J INTS Bio; Therapex Other, Advisory role. Champions Oncology; Crown Bioscience; Imagen; PearlRiver Bio GmbH Patent, Other Intellectual Property. Theravance; Gencurix; Bridgebio; Kanaph Therapeutics; Cyrus Therapeutics; Interpark Bio; J INTS BIO Stock. AstraZeneca; Dong-A-ST; Champions Oncology; Janssen; Yuhan; MSD; GI Innovation; CJ Bioscience; Cyrus Therapeutics; ImmuneOncia; Therapex; J INTS BIO; Vertical Bio AG ). DAAN Biotherapeutics Other. T. Yoshida, Novartis; AbbVie; Amgen; Daiichi-Sankyo; AstraZeneca; MSD; Chugai Pharmaceutical Co, ltd; Astellas; Boehringer Ingelheim; Bristol-Myer Squibb; Ono Pharmaceutical; Merck Biopharma ). Amgen; Novartis; Daiichi-Sankyo; AstraZeneca; MSD; Chugai Pharmaceutical Co. ltd; Bristo-Myer Squibb; Ono; Takeda; Pfizer; Lilly; Merck Biopharma Other, Honoraria. Novartis; MSD; Amgen; Chugai Pharmaceutical Co. ltd; Daiichi-Sankyo; Pfizer; Boehringer Ingelheim Other, Advisory role. D. Haggstrom, None. S. Kao, AstraZeneca; Pfizer; MSD; Bristol-Myers Squibb; Roche; Amgen; Beigene; Boehringer Ingelheim; Daiichi Sankyo Other, Advisory role. MSD, Bristol-Myers Squibb; Roche; AstraZeneca; Pfizer; Boehringer Ingelheim; Takeda; Beigene; Daiichi Sankyo Other, Honoraria. Pfizer Travel. A. Swalduz, Amgen; AstraZeneca; Roche; Sanofi; Janssen; Pfizer; Takeda; Daiichi Sankyo; MSD Other, Honoraria. Roche; Janssen; Pfizer; Takeda Travel. M. Nagasaka, AstraZeneca; Caris Life Sciences; Daiichi Sankyo; Takeda; Pfizer; Lilly; Genentech; Bristol-Myers Squibb; Regeneron; Boehringer Ingelheim; Johnson & Johnson Other, Advisory role. Takeda; Pfizer; Johnson & Johnson; Bristol-Myers Squibb Other, Speakers' Bureau. Anheart Therapeutics Travel. MBrace Therapeutics Stock. B. J. Solomon, Bristol-Myers Squibb; MSD; AstraZeneca; Pfizer; Roche/Genentech; Amgen; Lilly; BeiGene; Takeda; GlaxoSmithKline; Johnson & Johnson/Janssen; Nuvalent Other, Advisory role. UpToDate Other. AstraZeneca; MSD; Roche/Genentech; Pfizer; Amgen Other, Honoraria. L. Landi, Pfizer Other, Consulting, Speakers' Bureau. AstraZeneca Other, Consulting, Speakers' Bureau. Roche Other, Consulting, Speakers' Bureau. Bristol Myers Squibb Other, Consulting, Speakers' Bureau. MSD Other, Consulting, Speakers' Bureau. Amgen Other, Consulting, Speakers' Bureau. Abbvie Other, Consulting. Johnson & Johnson Other, Consulting, Speakers' Bureau. Lilly Other, Speakers' Bureau. Daiichi Sankyo Other, Consulting. Thermofisher Other, Speakers' Bureau. C. Bennati, None. E. Pons-Tostivint, AstraZeneca; Bristol-Myers Squibb; Sanofi; Pfizer; Daiichi Sankyo; Johnson & Johnson; Amgen; Roche; PharmaMar Other, Advisory role. C. Dooms, Janssen Other, Advisory role. A. J. van der Wekken, None. S. Waqar, AstraZeneca; Gilead Sciences; Pfizer; Johnson & Johnson/Janssen; Daiichi Sankyo; Boehringer Ingelheim; Amgen; Adcendo Other, Advisory role. Daiichi Sankyo; Xcovery; AstraZeneca; Abbvie; Roche; Lilly; Genetech; Elevation Oncology; Janssen; Ribon Therapeutics; Nuvalent ). S. Gadgeel, Genentech/Roche; AstraZeneca; Bristol-Myers Squibb; Takeda; Daiichi Sankyo; Lilly; Pfizer; Mirati Therapeutics; Merck; Eisai; Gilead Sciences; Arcus Biosciences; Bayer; Regeneron; Abbvie Other, Advisory role. Astellas Pharma; Johnson & Johnson/Janssen Other, Advisory role. Mirati Therapeutics; Merck Travel. AstraZeneca Other. Genentech/Roche; Merck; Astellas Pharma; Daiichi Sankyo; AstraZeneca; Pfizer; Amgen; Turning Point Therapeutics; Regeneron; Mirati Therapeutics; Janssen Oncology; InvestisBio; eFFECTOR Therapeutics ). Heslsinn Therapeutics; Incyte; Numab; Verastem; Debiopharm Group; Nimbus Therapeutics; Bayer; Avistone Biotechnology; D3 Bio; Arcus Biosciences; Janux Therapeutics; ArriVent Biopharma; Genmab; GRAIL ). Iovance Biotherapeutics; Jacobio; Kymera; Abbvie; Monte Rosa Therapeutics; Novita Pharmaceuticals; Nuvalent; Revolution Medicines; Tango Therapeutics ). C. Lin, Novartis; Boehringer Ingelheim; Blueprint Medicines; Daiichi Sankyo; Abbvie; PharmaEngine; Bristol-Myers Squibb; Bayer; IMPAC Medical Systems; Anbogen Therapeutics Other, Advisory role. Lilly; Daiichi Sankyo; BeiGene; IMPAC Medical Systems Travel. Novartis; Roche; Daiichi Sankyo; Lilly Other, Honoraria. T. Kondo, None. H. Hayashi, AstraZeneca; Bristol-Myers Squibb; Daiichi Sankyo/UCB Japan; Janssen; Novocure; Abbvie; Chugai Pharma Other, Advisory role. Ono Pharmaceuticals; Bristol-Myers Squibb Japan; Lilly; AstraZeneca Japan; Chugai Pharma; Pfizer; Novartis; Amgen; Daiichi Sankyo/UCB Japan; Takeda; MSD KK; Janssen; Merck; Nippon BoehringerIngelheim Other, Honoraria. Novocure; Abbvie; Taiho Pharmaceutical; Hisamitsu Pharmaceutical; Eisai; CareNet; Nippon Kayaku; Kyowa Kirin; Reno Medical Other, Honoraria. IQVIA; Syneos Health; EPS Holdings; Nippon Kayaku; MSD; Amgen; Taiho Pharmaceutical; Bristol-Myers Squibb; CMIC CO Ltd; Pfizer; Labcorp Drug Development; Kobayashi Pharmaceutical; Pfizer; Abbvie ). A2 Healthcare; Lilly Japan; Medpace; GlaxoSmithKline KK; Sanofi; Chugai Pharma; Nippon Boehringer Ingelheim; PRA Health Sciences; Astellas Pharma; Ascent Development Services; Eisai; Bayer Yakuhin ). AstraZeneca Japan; Daiichi Sankyo; Novartis; Merck; Kyowa Kirin; PPD-SNBL; Sysmex; Nippon Kayaku; ICON Clinical Research GK; Mochida Pharmaceutical Co Ltd ). D. Tan, Merck; AstraZeneca; Roche; Pfizer; Amgen; DKSH; Bayer; Genmab; Zymeworks; Regeneron; PRISM.AI; Astellas Pharma; BeOne Medicines Other, Advisory role. HUTCHMED g., Board of Directors, non-salaried role). Pfizer; Boehringer Ingelheim; Roche; Brilliant Pharmaceuticals Travel. PRISM.AI Stock. Takeda; Novartis; Roche; Pfizer; Merck Other, Honoraria. Novartis; GlaxoSmithKline; AstraZeneca; ACM Biolabs; Pfizer ). G. Pasello, AstraZeneca; Amgen; Bristol-Myer Squibb; Johnson & Johnson; Lilly; MSD; Merk; Novartis; Pfizer; Regeneron; Roche; Fidia; PharmaMar Other, Advisory role/consultant/speaker's fees. AstraZeneca; Amgen; Bristol-Myer Squibb; Johnson & Johnson Lilly; MSD; Nuvalent; Roche; Pfizer; PharmaMar ). M. Duca, None. L. G. Paz-Ares, Lilly, MSD; Roche; Pharmamar; Merck; AstraZeneca; Novartis; Amgen; Pfizer; Sanofi; Bayer; Bristol-Myers Squibb; Mirati Therapeutics; GlaxoSmithKline; Janssen; Takeda;Regeneron;Abbvie; Astellas Pharma Other, Advisory role. ALTUM Sequencing; Stab Therapeutics g., Board of Directors, non-salaried role). MSD Oncology; Bristol-Myers Squibb; Roche/Genentech; Pfizer; Lilly; AstraZeneca; Merck Serono; BeiGene; Amgen; Daiichi Sankyo Europe GmbH Other, Speakers' Bureau. Altum Sequencing; Stab Therapeutics Stock. Roche/Genentech; Lilly; Pfizer; Bristol-Myers Squibb; MSD; AstraZeneca; Merck Serono; PharmaMar; Novartis; Amgen; Sanofi; Bayer; Takeda; Daiichi Sankyo; GlaxoSmithKline; Janssen; Medscape; Regeneron Other, Honoraria. Boehringer Ingelheim; Abbvie; Gilead Sciences; BeOne Medicines Other, Honoraria. Bristol-Myers Squibb; AstraZeneca; PharmaMar; MSD; Pfizer; ). A. Calles, Boehringer Ingelheim; Roche/Genentech; Lilly; MSD; Novartis; Pfizer; Bristol-Myers Squibb; Takeda; IGEN BIOTECH; Sanofi/Regeneron; Merck Serono; Daiichi Sankyo Europe GmbH; Summit Therapeutics Other, Advisory role. Johnson & Johnson/Janssen; BeiGene; Pierre Fabre; PharmaMar; RayzeBio Other, Advisory role. MSD Oncology; Pfizer; Boehringer Ingelheim; Roche; Johnson & Johnson/Janssen Travel. AstraZeneca; Boehringer Ingelheim; Pfizer; Roche/Genentech; Lilly; Novartis; MSD; Bristol-Myers Squibb; Amgen; Bayer; Takeda; Sanofi/Regeneron; Merck KGaA; PharmaMar; BeiGene Other, Honoraria. Daiichi Sankyo Europe GmbH; Pierre Fabre; Johnson & Johnson/Janssen Other, Honoraria. MSD Oncology; Pfizer ). E. Felip, Abbvie; Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; GlaxoSmithKline; MSD; Pfizer; Regeneron; Daiichi Sankyo Europe GmbH; Johnson & Johnson/Janssen; Pierre Fabre; Genentech/Roche Other, Advisory role. PharmaMar; Seagen; iTEOS Therapeutics; Tubulis GmbH Other, Advisory role. GRIFOLS Other. Amgen; Daiichi Sankyo Europe GmbH; MSD; Pfizer; Lilly; Roche; Gilead Sciences; Janssen/Johnson & Johnson Other, Honoraria. J. Mazieres, Roche/Genentech; Pfizer; Bristol-Myers Squibb; Lilly/ImClone; MSD; AstraZeneca; Pierre Fabre; Amgen; Revolution Medicines Other, Advisory role. Pfizer; MSD; Amgen Travel. Roche; Bristol-Myers Squibb; AstraZeneca; Pierre Fabre ). A. de Langen, AstraZeneca; Bristol-Myers Squibb; MSD Oncology; Roche; Boehringer Ingelheim; Pfizer; Lilly; Blueprint Medicines Other, Advisory role. AstraZeneca; Bristol-Myers Squibb; Merck Serono; MSD Oncology; Roche; Merus ). A. T. Shaw, Novartis Institutes for BioMedical Research; Amgen Employment. Pfizer; Tango Therapeutics; Nuvalent; Triana; Genentech/Roche; Novartis; Bridgebio; Astellas Pharma; Revolution Medicines; Merck; Alterome Therapeutics; Rigel Other, Advisory role. Novartis Institutes for BioMedical Research; Amgen Travel. Nextech Invest; EcoR1 Capital Other. Novartis Institutes for BioMedical Research Stock. Bristol-Myers Squibb ). J. W. Riess, Daiichi Sankyo; Bristol-Myers Squibb/Celgene; Janssen Oncology; Genentech; Regeneron; Amgen; Merck; Pfizer; GlaxoSmithKline; RepIimune; Oncohost; Bicycle Therapeutics; ArriVent Biopharma; Nuvalent Other, Advisory role. AstraZeneca; Nuvation Bio; Taiho Pharmaceutical; Verastem; Boehringer Ingelheim; Natera; Foundation Medicine Other, Advisory role. IO Biotech; GlaxoSmithKline Travel. Merck; AstraZeneca/MedImmune; Boehringer Ingelheim; Novartis; Revolution Medicines; ArriVent Biopharma; IO Biotech; Summit Pharmaceuticals; Nuvalent; Pfizer; Blossom Hill; Prelude Therapeutics ). Bicycle Therapeutics ). M. Garassino, Bristol-Myers Squibb; MSD; AstraZeneca; Novartis; Takeda; Roche; Sanofi; Celgene; Daiichi Sankyo; Pfizer; Seagen; Lilly; GlaxoSmithKline; Bayer; Blueprint Medicines; Janssen; Regeneron; Bayer; Abbvie Other, Advisory role. Mirati Therapeutics; Merck; Boehringer Ingelheim; Abion; Gilead Sciences; IO Biotech; Novocure; Janssen Oncology; Revolution Medicines Other, Advisory role. AstraZeneca; MSD Oncology; Merck; Mirati Therapeutics; Daiichi Sanky/AstraZeneca Other, Speakers' Bureau. Pfizer; Roche; AstraZeneca; Merck Travel. MSD Oncology; AstraZeneca/MedImmune; GlaxoSmithKline; Takeda; Roche; Bristol-Myers Squibb; Daiichi Sankyo/AstraZeneca; Regeneron; Pfizer; Blueprint Pharmaceuticals; Noravtis; Sanofi/Aventis; Medscape Other, Honoraria. Oncohost; Revolution Medicines Other, Honoraria. Bristol-Myers Squibb; MSD; Roche/Genentech; AstraZeneca/MedImmune; AstraZeneca; Pfizer; GlaxoSmithKline; Novartis; Merck; Incyte: Takeda; Spectrum Pharmaceuticals; Blueprint Medicines; Lilly ). AstraZeneca; Ipsen; Janssen; Exelixis; MedImmune; Sanofi; Pfizer; Amgen ). E. Shum, AstraZeneca; Janssen; Genentech; Blueprint Medicines; Boehringer Ingelheim; Regeneron; Gilead Sciences; Bristol-Myers Squibb/Roche Other, Advisory role. AstraZeneca; Boehringer Ingelheim; Janssen Travel. Delfi Diagnostics ). C. S. Baik, AstraZeneca; Pfizer; Janssen; Boehringer Ingelheim; Daiichi Sankyo/UCB Japan; Genentech/Roche; Bristol-Myers Squibb; Natera; Takeda; Regeneron; Lilly; Nuvalent Other, Advisory role. AstraZeneca; Pfizer; Blueprint Medicines; Daiichi Sankyo; Abbvie; TP Therapeutics; Lilly; Janssen; Nuvalent; Boehringer Ingelheim; Black Diamond Therapeutics; Bristol-Myers Squibb Foundation ). Ellipses Pharma; Systimmune; Blossom Hills; Summit Therapeutics ). J. R. Bauman, Pfizer; EMD Serono; Delcath Systmes; Merus; Innovent Biologics Other, Advisory role. Delcath Systems; Merus Travel. D. Camidge, Roche; Takeda; AstraZeneca; Daiichi Sankyo; Abbvie; Apollomics; Lilly; Nuvalent; Kestrel Labs; Janssen Other, Honoraria. Inivata ). C. Lin, AstraZeneca; F. Hoffman-La Roche AG; Boehringer Ingelheim; Pfizer; Merck; Chugai Pharma Other, Speakers' Bureau. G. Chang, AstraZeneca; Novartis; Pfizer; Boehringer Ingelheim; F. Hoffman-La Roche, Ltd; Eli Lilly and Company Oncology; MSD; Takeda; Amgen; Bristol-Myers Squibb; Ono Pharma Taiwan Co. Ltd; Daiichi Sankyo Other, Honoraria. D. Kim, Amgen; AstraZeneca; GlaxoSmithKline; Johnson & Johnson/Janssen; Merck; MSD; Boehringer Ingelheim; BridgeBio Therapeutics; Daiichi Sankyo; Bristol-Myers Squibb; Chong Keun Dang; IMBdx; Merus NV Other. Mirati Therapeutics; Merck; Novartis; Pfizer; Roche/Genentech; Takeda; Yuhan; Zymeworks Other. Alpha Biopharma; AstraZeneca/MedImmune; Hanmi; Janssen; Merus; Mirati Therapeutics; MSD; Novartis; Ono Pharmaceutical; Pfizer; Roche/Genentech; Takeda; TP Therapeutics; Xcovery; Yuhan ). Boehringer Ingelheim; Amgen; Daiichi Sankyo; Chong Kun Dang Pharmaceutical; BridgeBio Pharma; GlaxoSmithKline; Merck; inno.N; IMBdx; Zymeworks ). M. Ahn, AstraZeneca; MSD; Takeda; Amgen; Merck Serono; Pfizer; Yuhan; Daiichi Sankyo/AstraZeneca; Genexine; Voronoi Health Analytics; Boehringer Ingelheim Other, Advisory role. AstraZeneca; MSD; Takeda; Amgen; Merck Serono; Yuhan; Daiichi Sankyo/AstraZeneca; Boehringer Ingelheim Other, Honoraria. J. Han, Johnon & Johnson Other, Honoraria, Speakers' Bureau. Pfizer ), Other, Honoraria, consulting. Merck Other, Honoraria, consulting. AstraZeneca Other, Consulting, Speakers' Bureau. Boehringer Ingelheim Other, Consulting. Amgen Other, Consulting. Abbvie Other, Consulting. Daiichi Sankyo Other, Consulting, Speakers' Bureau. Daewoong, Other, Consulting. Roche Other, Consulting. Speakers' Bureau. Yuhan Other, Speakers' Bureau. K. Ninomiya, MSD KK; Chugai Pharmaceutical; Ono Pharmaceutical; Lilly Japan; Bristol Myers Squibb; Nippon Kayaku; AstraZeneca; Daiichi-Sankyo; Takeda Pharmaceutical; Taiho Pharmaceutical; Amgen; Kyowa Kirin Other, Honoraria. Janssen Pharmaceutical Other, Honoraria. R. Ariyasu, Astra Zeneca; Chugai Pharmaceutical; MSD; ONO Pharmaceutical; Bristol Myers Squib Other, Honoraria. R. Soo, AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Novartis; Pfizer; Roche/Genentech; Taiho Pharmaceutical; Yuhan; Takeda; Amgen; Lilly; Merck; Janssen; Puma Biotechnology; Merck Serono; Bayer Other, Advisory role. Thermo Fisher Scientific; J INTS BIO; Anheart Therapeutics; Daiichi Sankyo/AstraZeneca; GlaxoSmithKline; Sanofi Other, Advisory role. AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; Novartis; Pfizer; Roche/Genentech; Takeda; Yuhan; Amgen; Bayer; Merck; Merck Serono; Puma Biotechnology; J INST BIO; Agilent; Genmab Other, Honoraria. Anheart Theraepeutics; Daiichi Sankyo/AstraZeneca; Johnson & Johnson/Janssen; Novartis; Sanofi; Abbvie; Taiho Onoclogy; Takeda; Thermo Fisher Scientific; Chugal Pharma Other, Honoraria. AstraZeneca; Boehringer Ingelheim; Pfizer ). S. Popat, Boehringer Ingelheim; Roche; Pfizer; AstraZeneca; Bristol-Myers Squibb; MSD; Guardant Health; Takeda; Bayer; Daiichi Sankyo; Janssen; GlaxoSmithKline; Lilly; Merck KGaA; Amgen; Pfizer; Pierre Fabre Other, Advisory role. Anheart Therapeutics; Arcus Biosciences; Ellipses Pharma; Erasca, Inc; Gilead Sciences; PharmaMar; BioNTech; Genmab; IO Biotech; Nuvalent; Servier; Other, Advisory role. Summit Therapeutics; Taiho Oncology; Bicycle Therapeutics Other, Advisory role. Roche/Genentech; Gilead Biosciences Travel. Boehringer Ingelheim; Epizyme; Bristol-Myers Squibb; Clovis Oncology; Roche; Lilly; Takeda; Celgene; Novartis; ARIAD; MSD; Daiichi Sankyo; Guardant Health; Janssen; GlaxoSmithKline ). Mirati Therapeutics; Trizell; Turning Point Therapeutics; Amgen; AstraZeneca ). J. Wolf, Abbvie; AstraZeneca; Bristol-Myers Squibb; Boehringer Ingelheim; Ignyta; Lilly; Novartis; Pfizer; Roche; Janssen; Loxo/Lilly; Blueprint Medicines; Amgen; Takeda; Bayer; Daiichi Sankyo Europe GmbH Other, Advisory role. Seagen; Nuvalent; Merck; Mirati Therapeutics Other, Advisory role. AstraZeneca; Amgen; Janssen; Mirati Therapeutics; Novartis; Pfizer; Merck; Sanofi; Intellisphere Travel. Abbvie; AstraZeneca; Bristol-Myers Squibb; Boehringer Ingelheim; MSD; Novartis; Roche; Amgen; Bayer; Blueprint Medicines; Daiichi Sankyo Europe GmbH; Janssen; Lilly; Pfizer; Seagen; Takeda; Nuvalent Other, Honoraria. Mirati Therapeutics; Merck; Amgen Astellas BioPharma; BeiGene; DISCO Pharmaceuticals; Ellipses Pharma; Regeneron; Genmab; Zuelling Pharma; Turning Point Therapeutics; Revolution Medicines Other, Honoraria. Kingyee Beiging Co LTD; Nuvation Bio Other, Honoraria. Bristol-Myers Squibb; Novartis; Pfizer; Janssen; AstraZeneca ). M. García Campelo, AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Janssen Oncology; MSD Oncology; Novartis; Pfizer; Roche/Genentech; Takeda Other, Advisory role. Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Janssen Oncology; Eli Lilly; MSD Oncology; Novartis; Pfizer; Roche; Sanofi/Aventis; Takeda; MSD Oncology Other, Speakers' Bureau. V. A. Upadhyay, Nuvalent, Inc. Employment, Stock, Stock Option. S. V. Liu, Genentech; Bristol-Myers Squibb; AstraZeneca; Takeda; Regeneron; Guardant Health; MSD Oncology; Jazz Pharmaceuticals; Daiichi Sankyo/UCB Japan; Novartis; Gilead Sciences; Merus; Abbvie; Amgen Other, Advisory role. Boehringer Ingelheim; Pfizer; Revolution Medicines; OSE Immunotherapeutics; Yuhan; GlaxoSmithKline; Natera; Johnson & Johnson/Janssen; Nuvalent; Systimmune; PharmaMar Other, Advisory role. Genentech/Roche; Merck; Alkermes; Merus; Elevation Oncology; Nuvalent; Gilead Sciences; Abbvie; Ellipses Pharma; Puma Biotechnology; OSE Immunotherapeutics; AstraZeneca; Cogent Biosciences ). Systimmune; Bristol-Myers Squibb Foundation; Duality Biologics; BioNTech; MediLink; Synthekine ).

← 返回 AACR 2026 检索